Preclinical Programs

We have 3 product candidates in preclinical studies.

ATA621 is precision targeted against antigens expressed by the BK virus using our selectively enhanced targeting technology. This product candidate is being studied for possible use as a treatment for severe BK virus infections. Most people are infected with the BK virus in childhood, causing a mild illness resembling a cold. Once a healthy person is infected, the BK virus stays in their body and remains silent (latent) as it is held in check by a healthy immune system. In people with a weakened immune system like organ transplant patients or HIV patients, the virus can reactivate and cause illness. In transplant patients, BK virus can cause severe hemorrhagic cystitis (bleeding and pain in the bladder) that may lead to death. In the case of kidney transplant patients, BK virus can infect the kidney and lead to loss of the transplanted organ.

ATA368 is precision targeted against antigens expressed by the Human Papilloma Virus (HPV) using our selectively enhanced targeting technology. This product candidate is being studied for possible use as a treatment for tumors caused by HPV. HPV is associated with several types of tumors including cancers of the cervix, oropharynx, rectum, and vagina and is thought to cause about 30,000 cancers each year in the US.

ATA274 is precision targeted against antigens expressed by the cytomegalovirus (CMV) using our selectively enhanced targeting technology.  This product candidate is being studied for use as a treatment for Glioblastoma multiforme (GBM). Glioblastoma multiforme is a primary brain tumor that occurs mostly in adults aged 45-70. Median survival for patients with GBM with optimal therapy is about 1 year.